

Directed Genetic Engineering of *Xanthomonas campestris*

CROSS-REFERENCE TO RELATED APPLICATION

5 This application claims priority under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/279,493 filed March 28, 2001, the disclosure of which application is incorporated herein by reference in its entirety.

BACKGROUND

10 Xanthan gum is a biosynthetic polysaccharide produced from glucose or other sugars by various bacterial species of the *Xanthomonas* genus *e.g.* *Xanthomonas campestris pv campestris* (herein after *X. campestris*). This gum is also referred to as "*Xanthomonas* hydrophilic colloid," or as "*Xanthomonas* heteropolysaccharide" or as "*Xanthomonas* gum". Before use, xanthan gum is purified *e.g.* separated from bacterial
15 contaminants. Xanthan gum preparation is described in U.S. Patents: 3,557,016; 3,481,889, 3,438,915 and 3,305,016, incorporated herein by reference in their entirety. Xanthan gum is widely used for a variety of commercial applications including food, oil field and other industrial uses.

Xanthan gum imparts a unique combination of texture, organoleptic properties
20 and stability to foods. In foods, xanthan gum provides stability and improves or modifies textural qualities, pouring characteristics, and cling. In beverages, a slight increase in viscosity imparts the sensation of enhanced body without reducing flavor impact. Partially replacing high concentrations of starch in many food systems with xanthan gum contributes to a more pseudoplastic rheology; the benefits are improved flavor release

and more pleasing texture. The synergistic reactivity of xanthan gum with galactomannans further expands its application potential.

Industrial applications of xanthan gum utilize its ability to provide formulations with properties such as long-term suspension and emulsion stability in alkaline, acid and salt solutions, temperature resistance and pseudoplasticity. Optimal fluids for oilfield uses have low viscosity at high shear rates (such as at the drilling bit) and high viscosity at low shear rates (as in the annular region). Xanthan gum solutions provide these properties. Differentiated xanthan gums emphasis properties such as solution clarity, low shear dispersion and enhanced acid stability.

For many applications, purified xanthan gum is mixed with other polysaccharides, *e.g.* mannans such as galactomannan. Xanthan gum is used in combination with mannans to make aqueous gels used in food, explosives and air treatment products. The combination is also used in the manufacture of controlled release oral solid dosage of pharmaceuticals. These other polysaccharides can be degraded by specific enzymes which reduce desired properties of a blended gum. Thus, when xanthan gum is mixed with galactomannans, the presence of the enzyme galactomannanase in the xanthan gum is undesirable.

Efforts to provide differentiated xanthan gum based on genetic alterations (U.S. Patent No. 5,514,791, incorporated herein by reference in its entirety) and efforts to broaden the range of appropriate substrates for *Xanthomonas* fermentations by classical selection (U.S. Patent No. 4,444,792, incorporated herein by reference in its entirety) and genetic engineering (Fu and Tseng (1990) *Appl. Environ. Microbiol.* 56(4):919-923, incorporated herein by reference in its entirety) have been described.

Previously, undesirable properties in xanthan gum were removed using chemical mutagenesis. However, because this type of mutagenesis is non-specific, chemically-mutagenized *Xanthomonas* strains that lacked a fully active enzyme of interest such as galactomannanase often exhibited decreased xanthan gum yield as well.

5 Knowledge of the gene set present in *X. campestris pv. campestris* as disclosed in U.S. application Serial No. 09/703,708 (incorporated herein by reference in its entirety) allows directed genetic engineering to decrease or increase specific protein production. For example, undesired activities of specific enzymes such as galactomannanase can be reduced or eliminated in xanthan gum. Other target enzymes can include amylase,
10 cellulase, extracellular protease, intracellular protease, and glucose dehydrogenase. Amylase is used by *X. campestris* to sacchrify corn syrups that are not already completely hydrolyzed; residual amylase could modify xanthan gum formulations containing corn syrup. Cellulase is used by *X. campestris* to digest cellulose in plant derived complex nitrogen sources; residual cellulase could modify xanthan gum formulations containing
15 carboxymethyl cellulose. Extracellular and intracellular proteases are used by *X. campestris* to digest protein in complex nitrogen sources; residual protease could modify xanthan gum formulations containing proteinaceous material. The activity of glucose dehydrogenase diverts carbon from gum formation and acidifies the medium requiring neutralization which results in the accumulation of salt in the product; removal of its
20 activity could improve xanthan gum quality.

Certain enzymes can be targeted for overexpression, *e.g.* enzymes of commercial significance such as galactomannanase, *e.g.* for paper bleaching applications, amylase, cellulase and extracellular protease.

A particularly preferred object of this invention is to use directed genetic engineering to “knock out” specific enzymes in *Xanthomonas*.

Another preferred object of this invention is to provide a recombinant strain of *Xanthomonas campestris* that is deficient in activity of at least one of the enzymes responsible for undesirable properties in xanthan gum.

SUMMARY OF THE INVENTION

This invention provides transformed cells and organisms having reduced activity of at least one protein which is functionally equivalent to at least one of a galactomannanase, amylase, cellulase, extracellular protease, intracellular protease, and glucose dehydrogenase. Such peptides are functionally equivalent to wild-type proteins having at least 65 percent or higher similarity, more preferably at least 75 percent or higher similarity, even more preferably at least 90 percent or higher similarity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 44 through 69. The reduced activity can be effected by the presence of anti-sense nucleic acid sequence or by modification of the nucleic acid sequence of the gene encoding said protein, *e.g.* providing said cell or organism with a recombinant nucleic acid sequence having at least one change as compared to a wild-type gene encoding said protein. For instance, the nucleic acid sequence encoding the protein can be reduced or increased by at least one nucleotide base, can be shuffled and/or can have at least one point mutation as compared to a wild-type gene encoding said protein. In certain aspects of this invention the nucleic acid sequence encoding the protein is reduced by two or more nucleotide bases as compared to a wild-type, even more preferably by a substantial

amount, *e.g.* a major amount. In more preferred aspects of the invention substantially all of the nucleic acid sequence encoding the protein is deleted from the genome of the cell or organism.

This invention also provides a cell or organism having enhanced activity of at least one protein which is functionally equivalent to at least one of a galactomannanase, amylase, cellulase, extracellular protease and intracellular protease. Such peptides are functionally equivalent to wild-type proteins having at least 50 percent or higher similarity, more preferably at least 75 percent or higher similarity, even more preferably at least 90 percent or higher similarity to the amino acid sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NOs: 44 through 68. Enhanced activity can be achieved by providing the cell or organism with (a) multiple recombinant copies of the nucleic acid sequence of the gene encoding the protein, (b) recombinant regulatory sequence operably linked to a gene encoding the protein, or (c) shuffled nucleic acid sequence as compared to a wild-type gene encoding the protein. In preferred aspects of this invention the nucleic acid sequence of the wild-type gene will have at least 80 percent identity with a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2 and 18 through 42.

Another aspect of this invention provides DNA constructs useful for preparing the recombinant cells or organisms with reduced or enhanced protein activity.

In a preferred aspect of this invention the organism having reduced or enhanced protein activity is a recombinant bacteria, *e.g.* a recombinant *Xanthomonas campestris* bacteria. A preferred aspect of this invention provides a method for producing xanthan gum which is substantially free of certain protein activity, *e.g.* galactomannanase activity

amylase activity, cellulase activity, extracellular protease activity, intracellular protease activity and/or glucose dehydrogenase activity . Such xanthan gum can be harvested from a cultured recombinant *Xanthomonas campestris* bacteria modified according to this invention.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a multiple sequence alignment of parts of three mannan endo-1,4-beta-mannosidases.

Figure 2 is a schematic representation of the suicide vector pTR213-b.

Figure 3 illustrates the construction of the allele exchange suicide plasmid pHL170 for deletion of *manA*.

Figure 4 illustrates allele exchange by “cross-in cross-out” via homologous recombination.

Figure 5 shows position of PCR primers for evaluation of *manA* gene in knock-out candidates and the expected lengths of PCR products.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

A. Definitions

As used herein “reduced protein activity” in a recombinant cell or organism is determined by reference to a wild-type cell or organism and can be determined by direct or indirect measurement. Direct measurement of protein activity might include an analytical assay for the protein, *per se*, or enzymatic product of protein activity. Indirect assay might include measurement of an property affected by the protein. For instance in

the case of galactomannanase activity can be conveniently measured by locust bean gum (LBG) viscosity loss in a xanthan gum composition, *e.g.* because galactomannanase enzymatically reduces locust bean gum. Desired levels of reduced protein activity will vary depending on the application and protein being reduced. In the case of xanthan gum production from a culture of recombinant *Xanthomonas campestris* with reduced galactomannanase activity the recombinant organism will have at least a 99% reduction in galactomannanase activity, more preferably a 99.9% reduction and even more preferably at least 99.99% reduction in galactomannanase activity as measured by a LBG viscosity loss assay as discussed in the examples below.

A protein activity may be reduced by a variety of mechanisms. Antisense RNA will reduce the level of protein expressed and the activity will be reduced as compared to wild-type expression levels. Alternately, a mutation in the gene coding for a protein may not decrease the protein expression, but instead interfere with the protein's function to cause reduced protein activity.

As used herein "sequence identity" refers to the extent to which two optimally aligned polynucleotide or peptide sequences are invariant throughout a window of alignment of components, *e.g.*, nucleotides or amino acids. An "identity fraction" for aligned segments of a test sequence and a reference sequence is the number of identical components which are shared by the two aligned sequences divided by the total number of components in reference sequence segment, *i.e.*, the entire reference sequence or a smaller defined part of the reference sequence. "Percent identity" is the identity fraction times 100.

Useful methods for determining sequence identity are disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073. More particularly, preferred computer programs for determining sequence identity include the Basic Local Alignment Search Tool (BLAST) programs which are publicly available from National Center
5 Biotechnology Information (NCBI) at the National Library of Medicine, National Institute of Health, Bethesda, Md. 20894; see BLAST Manual, Altschul *et al.*, NCBI, NLM, NIH; Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990); version 2.0 or higher of BLAST programs allows the introduction of gaps (deletions and insertions) into
10 alignments; BLASTX can be used to determine sequence identity between a polynucleotide sequence query and a protein sequence database; and, BLASTN can be used to determine sequence identity between sequences.

For purposes of this invention “percent identity” shall be determined using BLASTX version 2.0.14 (default parameters), BLASTN version 2.0.14, or BLASTP
15 2.0.14.

As used herein “peptide” means a compound with two or more amino acids linked in series by the carboxyl group of one amino acid to the amino group of the adjacent.

“Polypeptide” means a peptide having at least 10 amino acids and includes proteins and protein fragments. Polypeptides which are not 100% sequence identical can be
20 functionally equivalent because of conservative amino acid substitutions or because a segment of the protein performs the desired function. Polypeptides of the present invention also include protein homologs. Particularly preferred protein homologs are

selected from the group consisting of bacteria such as *E. coli*, *Bacillus thuringiensis*, and other microorganisms such as yeast and *Aspergillus nidulans*.

As used herein the term “functionally equivalent” as applied to peptides means that functionally equivalent peptides perform the same function in nature, albeit at
5 different levels of activity.

“Conservative amino acid substitutions” refer to substitutions of one or more amino acids in a peptide sequence with another amino acid(s) having similar side chains, resulting in a silent change. Conserved substitutes for an amino acid within a native wild-type amino acid sequence can be selected from other members of the group to which
10 the naturally occurring amino acid belongs. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of
15 amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Naturally conservative amino acids substitution groups are: valine-leucine, valine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, aspartic acid-glutamic acid, and asparagine-glutamine.

20 Polynucleotides can have sequence variability yet code for a functionally equivalent peptides due to codon degeneracy, conservative amino acid substitutions, reading frame positioning and the like. The term "codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without

effecting the amino acid sequence of an encoded polypeptide. The amino acid changes may be achieved by changing the codons of the polynucleotide sequence, *e.g.* according to the RNA codons given in the following Table.

Table 1

5

Amino Acids / abbreviations				Codons
Alanine	Ala	A		GCA GCC GCG GCU
Cysteine	Cys	C		UGC UGU
Aspartic acid	Asp	D		GAC GAU
Glutamic acid	Glu	E		GAA GAG
Phenylalanine	Phe	F		UUC UUU
Glycine	Gly	G		GGA GGC GGG GGU
Histidine	His	H		CAC CAU
Isoleucine	Ile	I		AUA AUC AUU
Lysine	Lys	K		AAA AAG
Leucine	Leu	L		UUA UUG CUA CUC CUG CUU
Methionine	Met	M		AUG
Asparagine	Asn	N		AAC AAU
Proline	Pro	P		CCA CCC CCG CCU
Glutamine	Gln	Q		CAA CAG
Arginine	Arg	R		AGA AGG CGA CGC CGG CGU
Serine	Ser	S		AGC AGU UCA UCC UCG UCU
Threonine	Thr	T		ACA ACC ACG ACU
Valine	Val	V		GUA GUC GUG GUU
Tryptophan	Trp	W		UGG
Tyrosine	Tyr	Y		UAC UAU

The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when identifying a gene, *e.g.* for deletion to reduce protein activity or synthesizing a gene for ectopic activity in a host cell to enhance protein activity, it is useful to include in the possible nucleic acid sequences to be used one having a nucleic acid sequence with a frequency of codon usage which approaches the frequency of preferred codon usage of the host cell.

By "% similarity" for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711) and the default settings for determining similarity. Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2:482-489, 1981) to find the best segment of similarity between two sequences.

As used herein the term "antisense" refers to a polynucleotide molecule with a nucleic acid sequence which is complementary to a specific nucleic acid sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method including synthesis or transcription. A complementary "antisense" molecule introduced into a cell can hybridize with a transcribed polynucleotide, *i.e.* mRNA, forming duplexes which block either further transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

As used herein, a nucleic acid molecule and/or polypeptide molecule, be it a naturally occurring molecule or otherwise, may be "substantially purified", if the

molecule is separated from substantially all other molecules normally associated with it in its native state. More preferably a substantially purified molecule is the predominant species present in a preparation. A substantially purified molecule may be greater than 60% free, preferably 75% free, more preferably 90% free, and most preferably 95% free from the other molecules (exclusive of solvent) present in the natural mixture. The term “substantially purified” is not intended to encompass molecules present in their native state.

As used herein, the term "biologically active," refers to a peptide having structural, regulatory, or biochemical functions of a naturally occurring molecule.

As used herein, the term “recombinant” refers to (a) molecules that are constructed outside of living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell, (b) molecules that result from the replication or expression of those molecules described in (a) above or (c) organisms that contain recombinant DNA or are modified using recombinant DNA, *e.g.* knock-out vectors.

As used herein, “disrupted/disruption” means that the gene does not encode or express wild-type peptide or encodes non-functional peptide or peptide having substantially reduced activity. Examples of a disrupted gene include genes with DNA deleted or inserted, and point mutations.

As used herein “flanking region” means the DNA on at least one side of a gene.

Flanking regions are used for example in knock-out constructs used to delete all or a part of a wild-type gene sequence from the chromosome of a cell or organism.

Variations in peptide activity can be achieved by mutagenesis; screening methods for obtaining a specified protein or enzymatic activity of interest are disclosed in US

Patent 5,939,250, the entirety of which is incorporated herein by reference. An alternative approach to the generation of variants uses random recombination techniques such as "DNA shuffling" as disclosed in US Patents 5,605,793; 5,811,238; 5,830,721; 5,837,458 and International Applications WO 98/31837 and WO 99/65927, the entirety of all of which is incorporated herein by reference. An alternative method of molecular evolution involves a staggered extension process (StEP) for *in vitro* mutagenesis and recombination of polynucleotide sequences, as disclosed in US Patent 5,965,408 and International Application WO 98/42832, the entirety of all of which is incorporated herein by reference. Other *in vitro* recombination methods are disclosed in US Patent application Serial No. 09/746,432, the entirety of which is incorporated herein by reference.

As used herein, the term "*manA* gene" means a DNA sequence that encodes a functional galactomannanase enzyme. Other genes useful in this invention are described in the table below.

Table 2

Amylases

SEQ NUM	SEQ ID	coding sequence	PEP NUM	Description
18	XAN10 C691:94 53_1291 3RC	1001-2461	44	alpha-amylase (EC 3.2.1.1) - <i>Xanthomonas campestris</i> gb AAA27591.1 (M85252) alpha-amylase [<i>Xanthomonas campestris</i>]
19	XAN10 C760:60 715_644 27RC	1001-2713	45	alpha-amylase (EC 3.2.1.1) - <i>Thermoactinomyces vulgaris</i> emb CAA49465.1 (X69807) alpha-amylase [<i>Thermoactinomyces vulgaris</i>]

Cellulases

SEQ NUM	SEQ ID	coding sequence	PEP NUM	Description
20	XAN10 C680:40 97_7053	1001-1957	46	ENDOGLUCANASE PRECURSOR (ENDO-1,4-BETA-GLUCANASE) (CELLULASE) pir A42649 cellulase (EC 3.2.1.4) precursor - Pseudomonas solanacearum gb AAA61980.1 (M84922) beta-1,4-endoglucase [Ralstonia solanacearum]
21	XAN10 C683:11 459_151 26	1001-2668	47	N/A
22	XAN10 C684:77 8_4526 RC	1001-2749	48	MAJOR EXTRACELLULAR ENDOGLUCANASE PRECURSOR (ENDO-1,4-BETA-GLUCANASE) (CELLULASE) pir JH0158 cellulase (EC 3.2.1.4) precursor - Xanthomonas campestris pv. campestris gb AAA27612.1 (M32700) major extracellular endoglucanase (engXCA) precursor [Xanthomonas campestris]
23	XAN10 C684:29 44_6611 RC	1001-2668	49	EXOGLUCANASE A PRECURSOR (EXOCELLOBIOHYDROLASE A) (1,4-BETA-CELLOBIOHYDROLASE A) (CBP95) pir S49541 cellulase - Cellulomonas fimi gb AAC36898.1 (L25809) cellulase [Cellulomonas fimi]
24	XAN10 C689:14 407_180 14	1001-2608	50	MAJOR EXTRACELLULAR ENDOGLUCANASE PRECURSOR (ENDO-1,4-BETA-GLUCANASE) (CELLULASE) pir JH0158 cellulase (EC 3.2.1.4) precursor - Xanthomonas campestris pv. campestris gb AAA27612.1 (M32700) major extracellular endoglucanase (engXCA) precursor [Xanthomonas campestris]
25	XAN10 C618 :3 52_3353	1001-2002	51	ENDOGLUCANASE PRECURSOR (ENDO-1,4-BETA-GLUCANASE) (CELLULASE) pir A42649 cellulase (EC 3.2.1.4) precursor - Pseudomonas solanacearum gb AAA61980.1 (M84922) beta-1,4-endoglucanase [Ralstonia solanacearum]

SEQ NUM	SEQ ID	coding sequence	PEP NUM	Description
26	XAN10 C618 :1 804_481 1	1001-2008	52	ENDOGLUCANASE PRECURSOR (ENDO-1,4-BETA-GLUCANASE) (CELLULASE) pir A42649 cellulase (EC 3.2.1.4) precursor – Pseudomonas solanacearum gb AAA61980.1 (M84922) beta-1,4-endoglucanase [Ralstonia solanacearum]

Extracellular Proteases

SEQ NUM	SEQ ID	coding sequence	PEP NUM	Description
27	XAN10 C665 :1 _2670R C	1001-2032	53	EXTRACELLULAR METALLOPROTEASE PRECURSOR pir A41048 extracellular metalloproteinase (EC 3.4.24.-) precursor – Erwinia carotovora subsp. Carotovora gb AAA24858.1 (M36651) extracellular protease (prt) [Pectobacterium carotovorum]
28	XAN10 C679 :1 7909_20 778RC	1001-1870	54	PROBABLE PROTEASE HTPX pir H64088 heat shock protein htpX – Haemophilus influenzae (strain Rd KW20) gb AAC22378.1 (U32755) heat shock protein (htpX) [Haemophilus influenzae Rd]
29	XAN10 C690 :4 862_860 4	1001-2743	55	EXTRACELLULAR PROTEASE PRECURSOR pir S11890 serine proteinase (EC 3.4.21.-) precursor, extracellular – Xanthomonas campestris pv. Campestris emb CAA35962.1 (X51635) protease [Xanthomonas campestris]
30	XAN10 C690 :8 825_122 76	1001-2452	56	EXTRACELLULAR PROTEASE PRECURSOR pir S11890 serine proteinase (EC 3.4.21.-) precursor, extracellular – Xanthomonas campestris pv. Campestris emb CAA35962.1 (X51635) protease [Xanthomonas campestris]
31	XAN10 C700 :1 472_512 1RC	1001-2650	57	(S51030) serine protease, AspA [Aeromonas salmonicida, ssp. Salmonicida, Peptide, 621 aa] prf 1907163A Ser protease [Aeromonas salmonicida salmonicida]

SEQ NUM	SEQ ID	coding sequence	PEP NUM	Description
32	XAN10 C731:46 4_3507 RC	1001-2044	58	N/A
33	XAN10 C747 :4 8081_51 868RC	1001-2788	59	Subtilisin BPN (E.C.3.4.21.14)
34	XAN10 C757 :1 8772_22 655	1001-2884	60	EXTRACELLULAR PROTEASE PRECURSOR pir S11890 serine proteinase (EC 3.4.21.-) precursor, extracellular – Xanthomonas campestris pv. Campestris emb CAA35962.1 (X51635) protease [Xanthomonas campestris]

5

Intracellular Proteases

SEQ NUM	SEQ ID	coding sequence	PEP NUM	Description
35	XAN10 C685:56 96_1057 5RC	1001-3880	61	(L43135) protease [Methylobacterium extorquens]
36	XAN10 C702:17 36_5022 RC	1001-2287	62	ATP-DEPENDENT CLP PROTEASE ATP- BINDING SUBUNIT CLPX pir A48709 ATP-dependent clp proteinase (EC 3.4.21.-) regulatory chain X - Escherichia coli gb AAA16116.1 (L18867) ATP-dependent protease ATPase subunit [Escherichia coli] gb AAB40194.1 (U82664) ATP-dependent Clp proteinase [Escherichia coli] gb AAC73541.1 (AE000150) ATP-dependent specificity component of clpP serine protease, chaperone [Escherichia coli K12]

10

SEQ NUM	SEQ ID	coding sequence	PEP NUM	Description
37	XAN10 C702:31 47_5764 RC	1001-1618	63	ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT (ENDOPEPTIDASE CLP) (CASEINOLYTIC PROTEASE) (PROTEASE TI) (HEAT SHOCK PROTEIN F21.5) pir B36575 ATP-dependent clp proteinase (EC 3.4.21.-) chain P - Escherichia coli gb AAA23588.1 (J05534) ATP-dependent protease (clpP) [Escherichia coli] gb AAB40193.1 (U82664) ATP-dependent Clp proteinase [Escherichia coli] gb AAC73540.1 (AE000150) ATP-dependent proteolytic subunit of clpA-cipP serine protease, heat shock protein F21.5 [Escherichia coli K12]
38	XAN10 C722:15 344_179 19	1001-1576	64	hypothetical 20.3 kD protein in sohA-mtr intergenic region - Escherichia coli (strain K-12) gb AAA57956.1 (U18997) ORF_o186 [Escherichia coli] gb AAC76187.1 (AE000396) orf, hypothetical protein [Escherichia coli K12]
39	XAN10 C756:44 20_8396	1001-2977	65	(M31045) ClpA protein [Escherichia coli]
40	XAN10 C756:57 26_8703	1001-1978	66	(M31045) ClpA protein [Escherichia coli]
41	XAN10 C773:39 836_431 88RC	1001-2353	67	CARBOXY-TERMINAL PROCESSING PROTEASE PRECURSOR (C-TERMINAL PROCESSING PROTEASE) gb AAB61766.1 (L37094) protease [Bartonella bacilliformis]
42	XAN10 C779:66 396_705 79	1001-3184	68	TAIL-SPECIFIC PROTEASE PRECURSOR (PROTEASE RE) (PRC PROTEIN) pir A41798 carboxy-terminal proteinase (EC 3.4.21.-) precursor - Escherichia coli gb AAA24699.1 (M75634) tail-specific protease [Escherichia coli] dbj BAA15638.1 (D90826) Tail-specific protease precursor (EC 3.4.21.-) (Protease RE) (PRC protein). [Escherichia coli] gb AAC74900.1 (AE000277) carboxy-terminal protease for penicillin-binding protein 3 [Escherichia coli K12]

Glucose Dehydrogenase

SEQ NUM	SEQ ID	coding sequence	PEP NUM	Description
43	XAN10 C711:13 605_180 16	1001-3412	69	GLUCOSE DEHYDROGENASE [PYRROLOQUINOLINE-QUINONE] pir JV0107 glucose dehydrogenase (pyrroloquinoline-quinone) (EC 1.1.99.17) - Escherichia coli dbj BAA05580.1 (D26562) 'glucose dehydrogenase (pyrroloquinoline- quinone)' [Escherichia coli] gb AAC73235.1 (AE000122) glucose dehydrogenase [Escherichia coli K12]

Table headings:

5 **SEQ NUM** is the SEQ ID NO of the polynucleotide in the sequence listing

SEQ ID is an arbitrary name

coding sequence gives the location of the region of the polynucleotide which is translated into a protein as determined by a gene-predicting program.

10 **PEP NUM** provides the sequence listing number for the translations of the coding sequences described immediately above.

Description When a coding region is revealed by a homology based gene prediction method, the sequence to which it shows homology receives a description based on its comparison to another sequence in a public database after BLAST or a similar algorithm is used. The description that query sequence receives is listed under this column heading.

15

B. Reduced Protein Activity

This invention provides transformed cells and organisms having reduced activity of at least one protein which is functionally equivalent to at least one of a galactomannanase, amylase, cellulase, extracellular protease, intracellular protease, and

glucose dehydrogenase. Such peptides are functionally equivalent to wild-type proteins having at least 50 percent or higher similarity, more preferably at least 75 percent or higher similarity, even more preferably at least 90 percent or higher similarity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 44

5 through 69. The reduced activity can be effected by the presence of anti-sense nucleic acid sequence or by modification of the nucleic acid sequence of the gene encoding said protein, *e.g.* providing said cell or organism with a recombinant nucleic acid sequence having at least one change as compared to a wild-type gene encoding said protein. For instance, the nucleic acid sequence encoding the protein can be reduced or increased by
10 at least one nucleotide base, can be shuffled and/or can have at least one point mutation as compared to the wild-type gene encoding said protein. In certain aspects of this invention the nucleic acid sequence encoding the protein is reduced by two or more nucleotide bases as compared to the wild-type, even more preferably by a substantial amount, *e.g.* a major amount. In more preferred aspects of the invention substantially all
15 of the nucleic acid sequence encoding the protein is deleted from the genome of the cell or organism.

A recombinant organism can be prepared by any of a variety of ways known to those skilled in the art, *e.g.* by homologous recombination using DNA constructs for providing a modified sequence or knocking out the wild-type sequence. Sequence for
20 knocking out a gene can comprise a modified wild-type gene, *e.g.* part of the gene sequence with an interim gap, or preferably flanking sequence for the gene where the interim gap comprises the gene *per se*. Preferably the construct comprises flanking sequence from both sides of the gene encoding the protein to be reduced, *e.g.* about 30

base pairs of flanking sequence from each side of the gene. Alternatively, the construct can comprise exogenous nucleic acid sequence flanked by sequence from said gene. In the case of knocking out a gene encoding a galactomannanase from *Xanthomonas campestris*, it is useful for the flanking sequences to comprise SEQ ID NOs: 6 and 7.

5

C. Enhanced Protein Activity

A further aspect of this invention provides a cell or organism having enhanced activity of at least one protein which is functionally equivalent to at least one of a galactomannanase, amylase, cellulase, extracellular protease and intracellular protease.

10 Such peptides are functionally equivalent to wild-type proteins having at least 50 percent or higher similarity, more preferably at least 75 percent or higher similarity, even more preferably at least 90 percent or higher similarity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 44 through 69 . Enhanced activity can be achieved by providing the cell or organism with (a) multiple recombinant copies
15 of the nucleic acid sequence of the gene encoding the protein, (b) recombinant regulatory sequence operably linked to a gene encoding the protein, or (c) shuffled nucleic acid sequence as compared to the wild-type gene encoding the protein. In preferred aspects of this invention the nucleic acid sequence of a wild-type gene will have at least 80 percent identity with a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
20 2 and 18 through 43.

DNA constructs for producing the transformed cell or organism with enhanced activity of protein can comprise at least one modified sequence of a wild-type gene or a regulatory region operably linked to a wild-type gene. Targets for overexpression have

desirable characteristics, for example, overexpression of mannanase is useful in bleaching paper, see US Patents 5,854,047 and 5,661,021, the entireties of all of which is incorporated herein by reference. In a preferred aspect of this invention the DNA construct will comprise a nucleic acid molecule having at least 85 percent sequence
5 identity with SEQ ID NOs: 2 and 18 through 43.

Another aspect of this invention provides methods for producing a transformed cell or organism having enhanced activity of at least one protein comprising transforming the cell or organism with a construct of this invention.

10 **D. DNA constructs of the invention**

The present invention also encompasses the use of nucleic acids of the present invention in recombinant constructs. Using methods known to those of ordinary skill in the art, a protein encoding sequence and/or regulatory sequence of the invention can be deleted by inserting flanking regions into constructs which can be introduced into a
15 *Xanthomonas* strain for the purpose of causing homologous recombination.

Furthermore, constructs may include those in which a *Xanthomonas* galactomannanase protein encoding sequence or portion thereof of the present invention is positioned with respect to a promoter sequence such that production of antisense mRNA complementary to native mRNA molecules is provided. In this manner,
20 expression and activity of the native gene may be decreased. The present invention also encompasses the use of nucleic acids of the present invention in constructs which provide for mutation of genes within *Xanthomonas* by homologous recombination. Such constructs, for example, may contain two regions of a protein encoding sequence harboring a heterologous portion of DNA (such as an antibiotic resistance marker)

between the two encoding segments. Such constructs may also contain, for example, other deletions, insertions, or base changes, or combinations thereof, relative to the *Xanthomonas*-derived DNA sequence. DNA shuffling may be used to modify the gene sequence to cause increased or decreased protein activity of the expressed protein.

- 5 Introduction of these constructs into a target organism, *e.g.* *Xanthomonas*, can be used to generate mutations in the DNA of that organism. Such directed mutations are useful, for example, for controlling activity of mutated genes *e.g.* reduction of galactomannanase activity by disruption of the *manA* gene in *X. campestris*.

- A further aspect of the present invention relates to recombinant vectors
- 10 comprising nucleic acid molecules of the present invention. In a preferred embodiment a recombinant vector includes at least one nucleic acid molecule of the present invention which can preferably be (a) homologous to regions flanking a protein encoding region of this invention or fragment or homolog thereof, (b) homologous to regions flanking a regulatory element, promoter or partial promoter, or (c) antisense to *manA* mRNA or
- 15 regulatory region or (d) homologous to a protein encoding region. In a further preferred embodiment of the present invention, a recombinant vector includes a regulatory element, promoter or partial promoter and a protein encoding region of the present invention, such nucleic acid molecules of the present invention having a sequence identified by SEQ ID
- 20 NOs: 2 and 18 through 43 or complements thereof or fragments of either encoding proteins having an amino acid sequence of SEQ ID NOs: 3 and 50 through 69. In another preferred embodiment of the present invention, the recombinant vector includes a regulatory element, promoter or partial promoter and a nucleic acid molecule encoding a *X. campestris* protein homolog or fragments thereof. Preferably, such recombinant

vectors of the present invention are introduced into a *Xanthomonas* species cell, more preferably a *X. campestris* cell, particularly a *X. campestris* strain NRRL B-1459 cell. It is also understood that such recombinant vectors may be introduced into any other cell or organism, including a plant cell, plant, fungal cell, fungus, mammalian cell, mammal, fish cell, fish, bird cell, bird or other (non-*Xanthomonas*) bacterial cell, so long as appropriate components, such as functional promoters, replication elements, and selectable markers are selected for the particular host to be transformed.

The recombinant vector of this invention may be any vector which can be conveniently subjected to recombinant DNA procedures. The choice of a vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector may be a linear plasmid or a closed circular plasmid. Examples of a method for homologous recombination using a linear vector is electroporation of linear DNA and a defective lambda prophage as described in Yu, Daiguan *et al.* (2000) *Proc. Natl. Acad. Sci. USA*, 97:5978-5983 or linear DNA and phage lambda Red recombinase, see Wanner, Barry *et al.* (2000) *Proc. Natl. Acad. Sci. U.S.A.*, 97: 6640-6645. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host. Methods of introduction of recombinant vectors into *Agrobacterium* species have been described and include triparental mating (Ditta *et al.* (1985) *Plasmid* 13:149-153; Ditta *et al.* (1980) *Proc. Natl. Acad. Sci. USA* 77:7347-7351) and electroporation (White *et al.* (1995) *Meth. in Mol. Biol.* 47:135-141).

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene

whose product provides, for example, biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Various selectable markers may be used depending upon the host species to be transformed, and different conditions for selection may be used for different hosts.

5 Those vectors of the present invention used for homologous recombination are preferably suicide vectors, see US Patent 4,634,678, incorporated herein by reference in its entirety. As used herein "suicide vector" means a vector without an origin of replication or a vector with an origin of replication that does not work in the target organism (it may be an *E. coli* origin of replication for amplification of the plasmid prior
10 to use in the target organism which is not *E. coli*).

 A nucleic acid sequence of the present invention may be operably linked to a suitable promoter sequence. A nucleic acid molecule of the present invention which encodes a protein or fragment thereof may also be operably linked to a suitable leader sequence. A leader sequence may be a nontranslated region of an mRNA which is
15 important for translation by a host cell. A leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the protein or fragment thereof. The leader sequence may be native to the nucleic acid sequence encoding the protein or fragment thereof or may be obtained from foreign sources. A polyadenylation sequence may also be operably linked to the 3' terminus of the nucleic acid sequence of the present
20 invention, particularly for use in eukaryotic host cells.

 To avoid the necessity of disrupting the cell to obtain the protein or fragment thereof, and to minimize the amount of possible degradation of the expressed protein or fragment thereof within the cell, it may be preferred that expression of the protein or

fragment thereof gives rise to a product secreted outside the cell, especially in the case of expression in bacterial host cells of bacterium or bacteria. To this end, the protein or fragment thereof of the present invention may be linked to a signal peptide at the amino terminus of the protein or fragment thereof. A signal peptide is an amino acid sequence which permits the secretion of the protein or fragment thereof from the host into the culture medium.

A polypeptide encoding a nucleic acid molecule of the present invention may also be linked to a propeptide coding region. A propeptide is an amino acid sequence found at the amino terminus of apoprotein or proenzyme. Cleavage of the propeptide from the proprotein yields a mature biochemically active protein. The resulting polypeptide is known as a propolypeptide or proenzyme (or a zymogen in some cases). Propolypeptides are generally inactive and can be converted to mature active polypeptides by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide or proenzyme. The propeptide coding region may be native to the protein or fragment thereof or may be obtained from foreign sources.

A polypeptide of the present invention may also be linked to a transit peptide coding region. A transit peptide is an amino acid sequence found at the amino terminus of an active protein which provides for transport of the protein into a plastid organelle, such as a plant chloroplast. The transit peptide coding region may be native to the type of cell to be transformed, or may be obtained from foreign sources.

An expressed polypeptide of the present invention may be detected using methods known in the art that are specific for the particular polypeptide. These detection methods may include the use of specific antibodies, formation of an enzyme product, or

disappearance of an enzyme substrate. For example, if the polypeptide has enzymatic activity, an enzyme assay may be used. Alternatively, if polyclonal or monoclonal antibodies specific to the polypeptide are available, immunoassays may be employed using the antibodies to the polypeptide. The techniques of enzyme assay and
5 immunoassay are well known to those skilled in the art.

The resulting polypeptide may be recovered by methods known in the arts. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The recovered polypeptide may then be further
10 purified by a variety of chromatographic procedures, *e.g.*, ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like.

E. Recombinant microorganisms

The present invention encompasses the use of recombinant microorganisms with
15 modified (reduced or enhanced) protein activity. In a preferred aspect of the invention the microorganism has reduced protein activity of at least one protein selected from the group having the function of at least one of galactomannanase, amylase, cellulase, extracellular protease, intracellular protease and glucose dehydrogenase. In a preferred aspect of this invention the organism having modified activity is a recombinant bacteria, *e.g.* a
20 recombinant *Xanthomonas campestris* bacteria. The reduction in translated protein activity by the transformed cell or organism is measured by reference to a wild-type cell or organism. In the case of *Xanthomonas campestris* the reference organism is conveniently *Xanthomonas campestris* strain NRRL-B 1459. A preferred embodiment of

the present invention is a recombinant *Xanthomonas campestris* strain comprising a specific targeted deletion of the *manA* coding region from the genome as exemplified in the examples herein as strain GMAN.

5 **F. Method of producing xanthan gum using a recombinant organism**

The fermentation of a culture of *Xanthomonas campestris* to produce xanthan gum is disclosed in US Patent 4,282,321, the entirety of which is incorporated herein by reference. Increased xanthan concentrations are obtained in *Xanthomonas* fermentations by addition of a source of assimilable carbon, *e.g.* glucose, corn syrup, *etc.*, to an aqueous
10 nutrient medium during the course of a fermentation cycle. See also US Patents 4,154,654; 4,394,447; 5,610,037; 5,756,317 and 6,033,896, the entireties of which are incorporated herein by reference.

15 **REFERENCES**

Each reference mentioned in this specification is incorporated by reference in its entirety. In addition, these references, as well as each of those cited can be relied upon to make and use aspects of the invention.

Example 1

This example serves to illustrate the identification of a galactomannanase gene in *X. campestris*. More particularly the following procedure demonstrates a TBLASTN homology search using the protein sequence of galactomannanase from two other organisms to query the *X. campestris* genome.

The sequence of two galactomannanases, *i.e.* from *Caldocellum saccharolyticum* (GeneBank:L01257.1) and *Streptomyces lividans* (GeneBank:M92297), are used to query the genomic sequence of *Xanthomonas campestris*. Each sequence is found to be most similar to the same open reading frame within contig XAN10C621 (SEQ ID NO: 1) of the *X. campestris* genome which is identified the “*manA*” gene and has the nucleic acid sequence of SEQ ID NO: 2. The *X. campestris manA* gene encodes a putative protein of 333 amino acids (called “MANA_XANCA” in Figure 1) having the amino acid sequence of SEQ ID NO: 3. The *X. campestris* codon frequency was obtained from the Internet site, Kazusa (www.kazusa.or.jp/codon/) and utilized with the GCG program Codon Preference. *X. campestris manA* appears to be a single gene that is not part of an operon because the genes predicted to flank *manA* within contig XAN10C621 (SEQ ID NO 1) are transcribed from the opposite strand as *manA* precluding the possibility that they could be co-transcribed with *manA*. *manA* is preceded by a poor ribosome binding site (CTGGAG, bp 3616-3621 of SEQ ID NO 1) and followed by a stem-loop structure (bp 4652-4682) with a $\Delta G = -10.2$ Kcal/mol.

As shown in Table 3, pair-wise comparisons of MANA_XANCA with the galactomannanases from *S. lividans* (MANA_STRLI having the amino acid sequence of Swiss Prot: P51529) and *C. saccharolyticum* (MANB_CALSA having the amino acid

sequence of Swiss Prot: P22533) were generated with GCG program BestFit using the BLOSUM62 scoring matrix. The numbers reported are % identity and, in parenthesis, % similarity.

Table 3

Proteins	MANA_STRLI	MANB_CALSA
MANA_XANCA	55.1 (61.7)	50.0 (58.6)
MANA_STRLI	--	55.9 (62.8)

From Table 3, it is apparent that the three proteins are $\geq 50\%$ identical to each other.

A multiple sequence alignment of the three predicted protein sequences is shown in Figure 1. The multiple sequence alignment comprises polypeptide sequences of MANA_XANCA (SEQ ID NO: 3), MANA_STRLI (SEQ ID NO: 16) and the beta-mannanase domain of MANB_CALSA (SEQ ID NO: 17). Amino acid residues that are conserved in all sequences are shaded. The indicated signal sequences for *S. lividans* MANA_STRLI and *C. saccharolyticum* MANB_CALSA are italicized. The identified glucosyl hydrolase family 5 signature sequences (PROSITE accession number PS00659) are boxed. The conserved glutamate (E) present within this signature sequence is believed to be the active site residue (shown in bold).

Example 2

This example serves to illustrate a method for disrupting the function of the *manA* gene identified in Example 1. More particularly, the *manA* gene is disrupted by deletion using a suicide plasmid containing DNA regions flanking the *manA* gene.

Allele exchange to result in the deletion of the *manA* gene of *X. campestris* pv *campestris* was accomplished in three steps: 1) construction of a suicide plasmid containing the regions flanking *manA* while omitting the *manA* coding region, 2) integration of the suicide plasmid at the homologous chromosomal locus and 3) excision of the *manA* gene and the vector sequence by a reciprocal homologous recombination. The suicide vector, pTR213-b, (Figure 2) was derived from pK19mobGII (Katzen, F., A. Becker, M. V. Ielmini, C. G. Oddo, and L. Ielpi. Appl. Environ. Microbiol. 65(1) 278-282 (1999)) by removal of the center portion of *gusA* with introduction of the *B. subtilis* *sacB* gene (Gay, P., D. LeCoq, M. Steinmetz, E. Farrari, and J. A. Hoch. Cloning structural gene *sacB*, which codes for exoenzyme levansucrase of *Bacillus subtilis*: expression of the gene in *Escherichia coli*. J. Bacteriol. 153(3) 1424-1431). pTR213-b contains the kanamycin resistance gene from Tn5, the *B. subtilis* *sacB* gene imparting sensitivity to sucrose, a multiple cloning site, and the *oriV* of pMB1 which will replicate independently in *E. coli* but will not replicate independently in *X. campestris*.

With reference to Figure 3, the first step involves generation by PCR of the regions A and B which flank *manA* and cloning the regions A and B into the plasmid in an orientation replicating that of the chromosome, omitting the coding frame of *manA*. Region A (SEQ ID NO: 6) represents the 5' flanking region which is upstream of the *manA* gene and Region B (SEQ ID NO: 7) represents the 3' flanking region which is downstream of the *manA* gene. After identifying the *X. campestris* *manA* gene illustrated in Example 1, a DNA plasmid was constructed to disrupt the single chromosomal *manA* gene in a strain of *X. campestris*. The deletion is generated on the plasmid by cloning the two flanking DNA regions while omitting the coding region for *manA* ($\Delta manA$).

The DNA regions A and B flanking the *manA* gene but not the *manA* gene itself were amplified by PCR and cloned into a vector, pTR213-b. Region A was amplified by PCR utilizing primers pMANA-1F (SEQ ID NO: 8) and pMANA-1R (SEQ ID NO: 9) (see table 4 for a detailed description of primers) which introduced *PstI* and *Sall* sites into the

5 amplified region A.

Table 4

Seq Num	Seq ID	Restriction Sites	Comments
8	pMANA-1F	<i>PstI</i>	amplify region A upstream of <i>manA</i> .
9	pMANA-1R	<i>Sall</i>	amplify region A upstream of <i>manA</i> .
10	pMANA-2F	<i>Sall</i>	amplify region B downstream of <i>manA</i> .
11	pMANA-2R	<i>XbaI</i>	amplify region B downstream of <i>manA</i> .
12	P57manA5		5' Primer to amplify <i>manA</i> allele.
13	p58manA3		3' Primer to amplify <i>manA</i> allele
14	PmanA2F		5' primer to amplify <i>manA</i> allele and utilized flanking sequence.
15	PmanA2R		3' primer to amplify <i>manA</i> allele and utilized flanking sequence.

Table headings:

Seq Num refers to the SEQ ID NO in the sequence listing.

10 **Seq ID** is an arbitrary name given to the primer.

Restriction Sites lists any restriction endonuclease sites designed into the primers.

Comments describes the use of the primer.

The amplified region A was digested with *PstI* and *Sall* and ligated to pTR213-b digested

15 with the same restriction enzymes. XL-Blue *E. coli* cells were electroporated with a fraction of the ligation mix and kanamycin resistant colonies were selected. pHL169 was

isolated from one of the kanamycin resistant colonies and demonstrated to be comprised of the expected 6.5 kb and 0.73 kb *PstI-SalI* fragments. pHL170 was constructed by addition of downstream region B juxtaposed to the upstream region A in pHL169.

Region B (SEQ ID NO: 7) was generated by PCR utilizing primers pMANA-2F (SEQ ID NO 10) and pMANA-2R (SEQ ID NO 11) which introduced *SalI* and *XbaI* sites into the amplified region B. These sites allowed cloning of the downstream fragment in the same orientation as the upstream fragment into *SalI*, *XbaI* digested pHL169. After electroporation, kanamycin resistant XL-Blue *E. coli* candidates were identified which contained plasmid with the expected 7.3 kb and 0.7 kb fragments upon *SalI*, *XbaI* digestion; one plasmid isolate was named pHL170 (Figure 3).

In the second step, transformed *X. campestris* candidates are generated by electroporation of the suicide knock-out plasmid containing both the upstream and downstream regions A and B flanking *manA* into the bacteria and selection by growing the target transformed *X. campestris* in the presence of kanamycin. Figure 4a shows plasmid pHL170 with one possible alignment of a homologous region in the plasmid and the corresponding region in the bacterial chromosomal DNA. Those bacteria integrating a plasmid by homologous recombination will survive kanamycin selection while those bacteria without an integrated vector will die. The chromosomal structure in bacteria with an integrated plasmid will include a deleted *manA* locus, the integrated plasmid and a wild-type *manA* locus, as shown in Figure 4b.

The plasmid pHL170 was introduced into a strain of *Xanthomonas campestris* by electroporation. *X. campestris* cells were grown to mid-log on TYE medium, collected by centrifugation and washed two times with de-ionized water. Cells were suspended in

1% of the initial volume of de-ionized water. pHL170 was purified from XL-Blue *E. coli* utilizing a Qiagen mini-spin kit. 3 µl of pHL170 were mixed with 50 µl of ice cold *X. campestris* electrocompetent cells in a 0.2 cm cuvet. The mixture was pulsed in a BioRad Pulser with nominal settings of 2.5 Kv, 1000 ohms, and 25 µF. The recorded pulse was 2.49 Kv, 22.5 msec. 2 ml of SOC at room temperature were immediately added and the mixture was incubated at 30°C, 250 rpm for 4 h. 10 µl and 100 µl aliquots were spread on TYE-Kan50 plates and incubated at 30° C for two days. 86 kanamycin resistant candidates were generated by this process.

Many Gram negative bacteria have been demonstrated to develop sensitivity to sucrose if the heterologous gene *sacB*, derived from *B. subtilis*, is introduced. The kanamycin survivors were grown in the presence of sucrose to enrich for clones from which the integrated plasmid had been lost by a reciprocal homologous recombination event. Two results can be obtained from the reciprocal homologous recombination eliminating the plasmid. Either wild-type sequence, including a functional *manA*, remains (Figure 4c), or the manufactured deletion remains in the chromosome (Figure 4d). Screening by phenotype or direct examination of chromosomal structure by PCR can be used to differentiate these two results. Selection for elimination of the integrated suicide plasmid was accomplished by growth on sucrose; selecting against strains which had not undergone a second homologous recombination event to remove a plasmid. Kanamycin resistant candidates were grown under non-selective conditions; passage in TYE medium at 30°C for two 24 hour cycles. Cultures were plated on 10% sucrose-TYE plates and colonies at two days were selected. 10% of the colonies proved kanamycin

resistant (still contained integrated plasmid) and were discarded. Sucrose tolerant, kanamycin sensitive colonies were examined further.

24 sucrose tolerant, kanamycin sensitive candidates were grown in liquid culture. Genomic DNA was prepared utilizing a MasterPure Kit (Epicentre, Madison, WI 53713) with conditions as recommended by the manufacturer. With reference to Figure 5, PCR was utilized to examine colonies for deletion of the *manA* gene. Two sets of primers were utilized to identify the clones in which excision of the suicide plasmid gene resulted in the $\Delta manA$ allele. The first set comprises primer P57manA3' (SEQ ID NO: 12) and primer P58manA5' (SEQ ID NO: 13) which lie within regions A and B. The second set comprises primer PmanA2F (SEQ ID NO: 14) and primer PmanA2R (SEQ ID NO: 15) which lie outside of regions A and B.

Figure 5 shows where each primer set is designed to anneal to the wild-type *manA* allele (Figure 5a) and to the recombinant $\Delta manA$ allele (Figure 5b). Using the first primer set (SEQ ID NOs: 12 and 13) the PCR products from wild-type allele should be about 1.4 Kb (Figure 5.a.1) and the PCR products from the recombinant $\Delta manA$ allele should be about 0.4 Kb (Figure 5.b.1). Using the second primer set (SEQ ID NOs: 14 and 15) the PCR products from wild-type allele should be about 2.9 Kb (Figure 5.a.2) and the PCR products from the recombinant $\Delta manA$ allele should be about 1.9 Kb (Figure 5.b.2).

PCR reactions contained 675 μ l of Master Mix, 135 μ l P58manA3, 135 μ l P57manA5, 375 μ l deionized water and 1 μ l genomic DNA. The PCR program included a denaturation step at 95° C for 15 minutes, 35 cycles of amplification with 1 minute at 95° C, 1 minute at 58° C, 1.5 minute at 72° C, a finishing step of 15 minutes at 72° C and

a quenching step at 4° C. Diluted pHL170 plasmid was used as a positive control ($\Delta manA$) and wild-type genomic DNA was utilized as a negative control (wild-type *manA*).

Fourteen isolates analyzed with the first set of primers yielded a single band of 0.4 kb indicating a $\Delta manA$ allele while seven isolates provided a single 1.4 kb band indicating a wild-type *manA* allele. The remaining three isolates had multiple bands indicating mixed colonies or unexpected arrangements resulting from the constructions. The positive control, pHL170, gave the expected 0.4 kb band and the negative control, wild-type genomic DNA gave the expected 1.4 kb band.

To confirm the constructs had the engineered deletion integrated at the native locus of *manA*, using the second set of primers, PCR reactions were run as described above resulting in 1.9 kb PCR products for all strains which had been indicated as $\Delta manA$. Controls suggested to be wild-type at the locus were confirmed by the generation of 2.9 kb PCR products. The 14 confirmed $\Delta manA$ isolates were named GMAN1 through GMAN14.

The GMAN strains are confirmed to deviate from wild-type by a chromosomal deletion of 1055bp. This deletion is believed to encompass the entire *manA* gene, which is 1002 bp long, plus 2bp of upstream flanking sequence and 51 bp of downstream flanking sequence.

Example 3

This example illustrates the reduced activity of galactomannanase of the GMAN

strain of *X. campestris* compared to a wild-type strain by a plate assay designed to screen for the enzymatic activity.

Both strains (wild-type and GMAN) were grown on agar plates containing 9 grams per liter (g/L) of locust bean gum (LBG) as the main carbon source. LBG is degraded by *X. campestris* cells that express a functional galactomannanase. The resulting sugars, including glucose, are used by *X. campestris* to produce xanthan gum. A visual determination of gumminess of the colonies on the agar plate (as reported in Table 5) is an indication of function of the galactomannanase encoded by *manA*. Plates with 10 g/L glucose are included as a control to distinguish between isolates which cannot produce xanthan gum from simple saccharides and those which cannot produce xanthan gum from a galactomannan, *e.g.* LBG.

Table 5

Strains	Degree of gum formation on plates with:	
	10g/L Glucose (YM plates)	9g/L Locust Bean Gum (LBG plates)
NRRL-B 1459	++++	+++
GMAN	++++	+

+ very slightly gummy

++ slightly gummy

+++ gummy

++++ very gummy

NRRL-B1459, a wild-type *X. campestris*, isolated by the USDA Northern Regional Research Laboratory (available from the USDA Agricultural Research Service Culture Collection, Microbial Properties Research Unit, National Center for Agricultural Utilization Research, 1815 N. University Street, Peoria, IL 61604), demonstrates a "gummy" colony morphology in plates with either glucose or LBG as the primary carbon source. This indicates the strain is capable of degrading LBG into simple saccharides which can be utilized in xanthan gum production, *i.e.* the strain elaborates galactomannanase activity. GMAN produces a "gummy" phenotype on plates with glucose as the primary carbon source but appears only very slightly mucoid on plates with LBG as the carbon source. These results demonstrate that deletion of the *mana* gene substantially reduces the ability of the GMAN strains to utilize galactomannan while xanthan gum production from glucose is unimpaired.

Example 4

This example illustrates the use of the GMAN strain of *Xanthomonas campestris* in the production of xanthan gum. More particularly, the following illustrates reduced galactomannanase activity of the GMAN strain compared to a wild-type strain of *X. campestris* as measured by a viscosity loss assay.

The endolytic cleavage of galactomannan by galactomannanase results in a loss of viscosity. This viscosity loss is the basis of an assay for the galactomannanase. A solution of LBG is treated with broth from a *X. campestris* fermentation. The time dependent loss of viscosity is indicative of the amount of galactomannanase produced by the *X. campestris*.

The substrate solution was prepared by dissolving locus bean gum to a concentration of 1% in de-ionized water, addition of 0.2 volumes of 5% KH_2PO_4 , pH 6.9 and pre-incubated at 40°C. Sample (1 ml of fermentation broth) or control (1 ml de-ionized water) was added to 100 ml of LBG substrate solution. The viscosity is measured with a Brookfield LVT viscometer (60 rpm, spindle #3) after 0, 3, 6 and 24 hours.

Typical viscosity results are shown in Table 6 below.

Table 6

Strain	Dilution	Viscosity (cP)			
		0 h	3 h	5 h	24 h
NRRL-B 1459	10-1	560	17	10	10
	10-2	820	226	106	17
	10-3	820	570	480	230
	10-4	886	658	650	556
GMAN#1	none	888	692	690	670
GMAN#2	none	980	715	750	760
GMAN#3	none	960	730	750	780
DI water	-----	820	620	640	600

Results show that there is a reduction in viscosity over the first three hours when GMAN broth is added to LBG solution. There is no further loss over the next 21 hours.

Comparison with the de-ionized water control demonstrates that the initial decrease is not related to galactomannanase in the sample. For comparison, dilutions, in de-ionized water, of fermentation broth from wild-type NRRL-B 1459 were assayed. Ten fold diluted broth from the wild-type strain eliminated essentially all viscosity within 3 hours.

Even 10,000 fold diluted broth, in 24 hours, destroyed 16% of the viscosity after

correcting for the viscosity loss observed with control over the first three hours. These data demonstrate a greater than 1000 fold reduction in endogalactomannanase activity in GMAN relative to a wild-type strain.

RECEIVED
JAN 10 2015
FBI
JAN 10 2015